AbbVie's Allergan Aesthetics Receives European Medicines Agency's Committee For Medicinal Products For Human Use's Positive Opinion Recommending Boey For Temporary Improvement In Appearance Of Moderate To Severe Lines Between Eyebrows At Maximum Frown

Allergan Aesthetics, an AbbVie company (NYSE:ABBV) and global leader in medical aesthetics, today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending approval of Boey® (trenibotulinumtoxinE) for the temporary improvement in the appearance of moderate to severe lines between the eyebrows seen at maximum frown (glabellar lines) in adult patients, when these have an important psychological impact. The European Commission decision, expected in the coming months, would apply across the 30 European Economic Area (EEA) countries following completion of the centralized procedure.